Ionis Pharmaceuticals Inc (IONS)
33.94
-1.46
(-4.11%)
USD |
NASDAQ |
Nov 21, 16:00
33.94
0.00 (0.00%)
After-Hours: 20:00
Ionis Pharmaceuticals Revenue (Quarterly): 133.81M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 133.81M |
| June 30, 2024 | 225.25M |
| March 31, 2024 | 119.50M |
| December 31, 2023 | 324.50M |
| September 30, 2023 | 144.21M |
| June 30, 2023 | 188.41M |
| March 31, 2023 | 130.52M |
| December 31, 2022 | 151.89M |
| September 30, 2022 | 159.77M |
| June 30, 2022 | 133.79M |
| March 31, 2022 | 141.92M |
| December 31, 2021 | 440.01M |
| September 30, 2021 | 133.09M |
| June 30, 2021 | 125.75M |
| March 31, 2021 | 111.61M |
| December 31, 2020 | 290.28M |
| September 30, 2020 | 160.08M |
| June 30, 2020 | 145.54M |
| March 31, 2020 | 133.37M |
| December 31, 2019 | 493.68M |
| September 30, 2019 | 167.89M |
| June 30, 2019 | 163.81M |
| March 31, 2019 | 297.21M |
| December 31, 2018 | 192.12M |
| September 30, 2018 | 145.40M |
| Date | Value |
|---|---|
| June 30, 2018 | 117.75M |
| March 31, 2018 | 144.42M |
| December 31, 2017 | 167.79M |
| September 30, 2017 | 118.31M |
| June 30, 2017 | 112.27M |
| March 31, 2017 | 115.80M |
| December 31, 2016 | 186.50M |
| September 30, 2016 | 110.93M |
| June 30, 2016 | 38.47M |
| March 31, 2016 | 36.87M |
| December 31, 2015 | 51.57M |
| September 30, 2015 | 49.12M |
| June 30, 2015 | 120.43M |
| March 31, 2015 | 62.58M |
| December 31, 2014 | 84.86M |
| September 30, 2014 | 44.06M |
| June 30, 2014 | 57.08M |
| March 31, 2014 | 28.16M |
| December 31, 2013 | 42.25M |
| September 30, 2013 | 23.58M |
| June 30, 2013 | 38.09M |
| March 31, 2013 | 43.36M |
| December 31, 2012 | 19.87M |
| September 30, 2012 | 11.60M |
| June 30, 2012 | 47.34M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
111.61M
Minimum
Mar 2021
493.68M
Maximum
Dec 2019
194.35M
Average
144.87M
Median
Revenue (Quarterly) Benchmarks
| Biogen Inc | 2.466B |
| Alnylam Pharmaceuticals Inc | 500.92M |
| Biomarin Pharmaceutical Inc | 745.74M |
| Amicus Therapeutics Inc | 141.52M |
| Arbutus Biopharma Corp | 1.339M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -140.48M |
| Total Expenses (Quarterly) | 282.43M |
| EPS Diluted (Quarterly) | -0.95 |
| Enterprise Value | 4.385B |
| Gross Profit Margin (Quarterly) | 99.20% |
| Profit Margin (Quarterly) | -105.0% |
| Earnings Yield | -7.19% |
| Normalized Earnings Yield | -8.933 |